Lionco: Wholly-owned subsidiary receives clinical trial approval notice for acetazolamide sustained-release capsule medication

Lionco announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. recently obtained the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration's Drug Evaluation Center for Acetazolamide Sustained-Release Capsules. This drug is suitable for the prevention or improvement of acute mountain sickness-related symptoms that may still occur under gradually rising conditions. Currently, there are no other companies in China applying for this product, and Lionco Pharmaceutical has invested research and development expenses of 6.9 million RMB